KineMed

Building on the companies' existing relationship, the deal licenses KineMed's proteomics platform to the pharmaceuticals giant for CDx development.

The partners will use KineMed's proteomics platform to evaluate the effect of biologics developed by Pronutria for metabolic and other diseases.

NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income.

NEW YORK (GenomeWeb News) – KineMed this week announced the renewal of its non-exclusive research collaboration with Pfizer into metabolic disease, and type 2 diabetes in particular.

NEW YORK (GenomeWeb News) – KineMed said this week that it has extended its collaboration with the CHDI Foundation on research into biomarkers for Huntington's disease.

KineMed has tapped Patrick Doyle to be executive VP and chief business officer. In the post, he will head corporate development activities, including licensing and strategic partnerships.

NEW YORK (GenomeWeb) – KineMed and CHDI Foundation today said they are extending their collaboration to characterize and track the pathogenesis of Huntington's disease and to evaluate possible therapeutic interventions.

NEW YORK (GenomeWeb News) – KineMed said today that it has entered an agreement with Amgen to apply its mass spec-based Dynamic Proteomics platform to the study of brain protein homeostasis in neurodegenerative disease.

NEW YORK (GenomeWeb News) – KineMed said today that it has received a $225,000 Phase I Small Business Innovation Research contract from the National Heart, Lung, and Blood Institute for research into biomarkers for the early detection of myocardial fibrosis.

Bruker has appointed Thomas Bachmann to be president of its Bruker BioSpin Group.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.